691 results about "Positron emission tomography" patented technology

Biopsy devices and methods useful with Positron Emission Tomography (PET) and Breast Specific Gamma Imaging (BSGI) are disclosed. A biopsy device including a flexible tube having a side aperture, and a PET or BSGI imageable material disposed within the flexible tube is disclosed. A biopsy method is disclosed that includes advancing a flexible tube having a PET or BSGI imageable material distally through the biopsy device. Various other embodiments and applications are disclosed.

Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.

The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.

Thiol-containing peptides can be radiolabeled with fluorine-18 (F-18) by reacting a peptide comprising a free thiol group with an F-18-bound labelling reagent which also has a group that is reactive with thiols. The resulting F-18-labeled peptides may be targeted to a tissue of interest using bispecific antibodies or bispecific antibody fragments having one arm specific for the F-18-labeled peptide or a low molecular weight hapten conjugated to the F-18-labeled peptide, and another arm specific to the targeted tissue. The targeted tissue is subsequently visualized by clinical positron emission tomography.

The radiolabeled non-natural amino acid 1-amino-3-cyclobutane-1-carboxylic acid (ACBC) and its analogs are candidate tumor imaging agents useful for positron emission tomography and single photon emission computed tomography due to their selective affinity for tumor cells. The present invention provides methods for stereo-selective synthesis of syn-ACBC analogs. The disclosed synthetic strategy is reliable and efficient and can be used to synthesize a gram quantity of various syn-isomers of the ACBC analogs, particularly, syn-[¹⁸F]-1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC) and syn-[¹²³I]-1-amino-3-iodocyclobutane-1-carboxylic (IACBC) acid analogs.

The present application relates to microfluidic devices and related technologies, and to chemical processes using such devices. More specifically, the application discloses a fully automated synthesis of radioactive compounds for imaging, such as by positron emission tomography (PET), in a fast, efficient and compact manner. In particular, this application describe an automated, stand-alone, microfluidic instrument for the multi-step chemical synthesis of radiopharmaceuticals, such as probes for PET and a method of using such instruments.

An ⁸²Sr/⁸²Rb generator column is made using a fluid impervious cylindrical container having a cover for closing the container in a fluid tight seal, and further having an inlet for connection of a conduit for delivering a fluid into the container and an outlet for connection of a conduit for conducting the fluid from the container. An ion exchange material fills the container, the ion exchange material being compacted within the container to a density that permits, the ion exchange material to be eluted at a rate of at least 5 ml/min at a fluid pressure of 1.5 pounds per square inch (10 kPa). The generator column can be repeatedly recharged with ⁸²Sr. The generator column is compatible with either three-dimensional or two-dimensional positron emission tomography systems.

A radiolabeled compound of a formula: is described. R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, hydroxy, alkoxy, halo, haloalkyl, carboxy, carbalkoxy and salts thereof; and A, B, C and D are each independently selected from the group consisting of a hydrogen and an electron withdrawing group, provided that at least one of A, B, C and D is [18]fluorine.

A method for acquiring PET images with reduced time coincidence window limits includes obtaining a preliminary image of a patient within a radiation field of view (FOV), determining the spatial location of the patient within the FOV based on the preliminary image, calculating a different time coincidence window based on the spatial location of the patient for each possible pair of oppositely disposed detectors, scanning the patient with a PET scanning system to detect a pair of gamma photons produced by an annihilation event, determining whether the detection of the pair of gamma photons occurs within the time coincidence window, accepting the detected event only if the detection of the gamma photons occurs within the time coincidence window, calculating the spatial location of accepted annihilation event, and adding the calculated spatial location of the annihilation event to a stored distribution of calculated annihilation event spatial locations representing the distribution of radioactivity in the patient.

Inventions relate to scintillation substances and they may be utilized in nuclear physics, medicine and oil industry for recording and measurements of X-ray, gamma-ray and alpha-ray, nondestructive testing of solid states structure, three-dimensional positron-emission tomography and X-ray computer tomography and fluorography. Substances based on silicate comprising lutetium and cerium characterised in that compositions of substances are represented by chemical formulae Ce_xLu_2+2y−xSi_1−yO_5+y, Ce_xLi_q+pLu_{2−p+2y−x−z}A_zSi_1−yO_5+y−p, Ce_xLi_q+pLu_{9.33−x−p−z}□_0.67A_zSi₆O_26−p, where A is at least one element selected from group consisting of Gd, Sc, Y, La, Eu, Tb, x is value between 1×10⁻⁴ f.units and 0.02 f.units., y is value between 0.024 f.units and 0.09 f.units, z is value does not exceeding 0.05 f.units, q is value does not exceeding 0.2 f.units, p is value does not exceeding 0.05 f.units. Achievable technical result is the scintillating substance having high density, high light yield, low afterglow, and low percentage loss during fabrication of scintillating elements.

Macro- and microfluidic devices and related technologies, and chemical processes using such devices. More specifically, the devices may be used for a fully automated synthesis of radioactive compounds for imaging, such as by positron emission tomography (PET), in an efficient, compact and safe to the operator manner. In particular, embodiments of the present invention relate to an automated, multi-run, microfluidic instrument for the multi-step synthesis of radiopharmaceuticals, such as PET probes, comprising a remote shielded mini-cell containing radiation-handing components.

A method and system for controlling a positron emission tomography (PET) system is disclosed. The method includes acquiring image data and time-of-flight information from a PET system during an imaging scan. Further, the method includes performing scatter correction on the image data using the time-of-flight information.

Biopsy devices and methods useful with Positron Emission Tomography (PET) and Breast Specific Gamma Imaging (BSGI) are disclosed. A biopsy device including a flexible tube having a side aperture, and a PET or BSGI imageable material disposed within the flexible tube is disclosed. A biopsy method is disclosed that includes advancing a flexible tube having a PET or BSGI imageable material distally through the biopsy device. Various other embodiments and applications are disclosed.

A high power high yield target for the positron emission tomography applications is introduced. For production of Curie level of Fluorine-18 isotope from a beam of proton it uses about one tenth of Oxygen-18 water compared to a conventional water target. The target is also configured to be used for production of all other radioisotopes that are used for positron emission tomography. When the target functions as a water target the material sample being oxygen-18 water or oxygen-16 water is heated to steam prior to irradiation using heating elements that are housed in the target body. The material sample is kept in steam phase during the irradiation and cooled to liquid phase after irradiation. To keep the material sample in steam phase a microprocessor monitoring the target temperature manipulates the flow of coolant in the cooling section that is attached to the target and the status of the heaters and air blowers mounted adjacent to the target. When the target functions as a gas target the generated heat from the beam is removed from the target by air blowers and the cooling section. The rupture point of the target window is increased by a factor of two or higher by one thin wire or two parallel thin wires welded at the end of a small hollow tube which is held against the target window. One or two coils are used to produce a magnetic filed along the beam path for preventing the density depression along the beam path and suppression of other instabilities that can develop in a high power target.

A positron emission tomography detector for a multilayer scintillation crystal comprises a plurality of layers of scintillation crystals, a photoelectric detector system and an algorithm system, wherein the multilayer scintillation crystals comprises n layers of array scintillation crystals and m layers of continuous scintillation crystals, both n and m are integers which are greater than or equal to 1, the sum of n and m is smaller than or equal to 10, the array scintillation crystals are formed by arraying strip-type scintillation crystals along the width and length directions, the continuous scintillation crystals are scintillation crystals which have uncut inner parts, the array scintillation crystals and the continuous scintillation crystals are sequentially coupled along the height direction of the strip-type scintillation crystals to form the multilayer scintillation crystals, and the bottoms of the continuous scintillation crystals are coupled with the photoelectric detector system. The positron emission tomography detector can more accurately obtain the position and the time of energy deposition of gamma photon in the scintillation crystal, and has higher detection efficiency of the gamma photon, the spatial resolution, the time resolution and the flexibility of a positron emission tomographic imaging system can be improved when the positron emission tomography detector is applied to the positron emission tomographic imaging system, and further, the imaging quality of the system can be improved.

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Alzheimer's disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as Alzheimer's or non-Alzheimer's dementia or normal. The biomarkers can be detected by SELDI mass spectrometry. In addition, the invention provides appropriate treatment interventions and methods for measuring response to treatment. Certain biomarkers of the invention may also be suitable for employment as radio-labeled ligands in non-invasive imaging techniques such as Positron Emission Tomography (PET).

Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.

This invention pertains to a method of low-cost intraoperative all field simultaneous parallel microbeam single fraction few seconds duration 100 to 1,000 Gy and higher dose radiosurgery with micro-electro-mechanical systems (MEMS)-carbon nanotube based microaccelerators. It ablates cancer cells including the mesenchymal epithelial transformation associated cancer stem cells. Microbeam brachy-therapeutic radiosurgery is performed. Microaccelerators are configured for simultaneous parallel microbeam emission from varying angels to an isocentric tumor. Their additive dose rate at the isocentric tumor is in the range of 10,000 to 20,000 Gy/s. It eliminates most tumor recurrence and metastasis which enhances cancer cure rates. It also exposes cancer antigens which induces cancer immunity. Stereotactic breast core biopsy is combined with, positron emission tomography and computerized tomography and phase-contrast imaging. Parallel microbeam brachytherapy preserves normal breast appearance. Migration of normal stem cells from unirradiated valley regions heals the radiation damage to the normal tissue.